New research shows 92% of cancer patients stayed cancer-free for two years after immune-based therapy, potentially avoiding ...

According to the results of the early study, published simultaneously in the New England Journal of Medicine, 92% of patients ...

Adding pembrolizumab (Keytruda), before and after surgery, to standard adjuvant therapy for locally advanced head and neck ...

For a limited group of cancer patients who have solid tumors in the stomach, rectum, esophagus and other organs, an ...

Immunotherapy let some cancer patients with mismatch repair deficient tumors completely avoid surgery, chemo and radiation, a ...

The session follows the American Association for Cancer Research's prior call to action against executive orders that would ...

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and ...

The addition of neoadjuvant and adjuvant pembrolizumab to standard of care significantly improved outcomes for certain ...

The AACR meeting was full of promising data on the vaccine against cervical cancer, a lung cancer drug and the next ...

We are navigating political interference, institutional instability, and growing uncertainty across the cancer research ...

Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...